For instance, empagliflozin monotherapy was found not to reduce postprandial glucose excursions or 24-h glucose variability (78), while when added to insulin therapy empagliflozin significantly lowered glucose excursions in type 2 and even in type 1 diabetes. Here, INS is linked to type 1 diabetes mellitus.